Climb Bio Inc CLYM

$9.19 -0.09 (-0.97%)

Valuation

Market cap
539,802,000
Revenue TTM
$0
Net income TTM
$-59,850,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
770,100
Avg volume
1,275,778
Day's range
$8.90 – $9.40
Shares out
58,738,000
Stochastic %K
8%
Beta
0.01
Analysts
Strong Buy
Price target
$28.40

Price

Company profile

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy...

Show more

Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
866 857 2596
Website
https://climbbio.com
Address
20 William Street, Suite G50, Wellesley Hills, United States

Latest news

Stocktwits

Quantumup Nov 18, 1:50 PM
RBC Capital reiterated $CLYM Outperform-$23. [ $JBIO $OTSKY VRTX RHHBY ARGX BIIB VERA TVTX ] Here's what RBC Capital said in its note: https://x.com/Quantumup1/status/2123050867951546413?a=1guBdwzuWePsBpyxhC8&s=20
0 replies
Quantumup Nov 18, 1:18 PM
BRiley reiterated $CLYM Buy-$30 after recently hosting an investor breakfast in London. [ $RHHBY $VRTX ARGX BIIB VERA TVTX JBIO ] BRiley said in its note: https://x.com/Quantumup1/status/2123043013865746851?a=e16RQ-5F9SI7fnPJAqk&s=20
0 replies
kubota2323 Nov 11, 3:24 PM
$XERS $CLYM $CADL giddy up.
0 replies
Merlintrader Nov 10, 6:44 PM
$CLYM Climb Bio (CLYM): cash $227.6M, runway into second half of 2028 Free weekly catalyst newsletter: https://merlintrader.beehiiv.com/p/week-ahead-10-catalysts-we-re-watching-november-9-13 Not investment advice.
0 replies
Merlintrader Nov 9, 6:51 PM
$CLYM Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates (Nov 5) • Climb Bio reported cash, cash equivalents and marketable securities of $227.6 million as of September 30, 2026, which the company expects to fund operations into the second half of 2028. • R&D expenses were $11.0 million for the three months ended September 30, 2026, compared to $9.1 million for the comparable 2025 period. • G&A expenses were $5.8 million in both periods, and other income, net was $2.3 million compared to $2.0 million. Full hub (catalysts, filings & latest news): https://www.merlintrader.com/climb-bio-clym-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=clym Free weekly catalyst newsletter — no free trials, no logins, FREE is FREE: https://merlintrader.beehiiv.com/subscribe?utm_source=stocktwits&utm_medium=social&utm_campaign=st-hub-giro&utm_content=clym Not investment advice.
0 replies
GTA_Terminal Nov 9, 12:18 PM
Unusual options activity in $CLYM. Money on both sides, which usually means traders expect a move but don't agree on the direction. Read the full article for the full details: https://globaltradersacademy.com/articles/climb-bio-clym-technical-levels-options-flow-mixed-between-10-07-and-11-26?utm_source=stocktwits&utm_medium=social
0 replies
mastersnafu Nov 5, 7:27 PM
$CLYM all my biotech stocks are getting smashed hard. Clym is recovering so this might be the beginning of another run hopefully
0 replies
Merlintrader Nov 5, 3:14 PM
$CLYM : Climb Bio Q3 2026 (reported Nov 5): Net loss $14.6M, $(0.18) per share; 9M loss $41.8M; cash and marketable securities $227.6M at Sept 30; runway into 2H 2028; Q3 R&D $11.0M; G&A $5.8M; NAVIGATE-2 Phase 2 IgAN dosing started; additional budoprutug ITP data at ASH Dec 2026. Questions worth checking: When is the next CLYM stock catalyst? How much cash does Climb Bio have? What is new on Climb Bio NAVIGATE-2? Answers, primary sources and downloadable PDF report in our hub: https://www.merlintrader.com/climb-bio-clym-stock-hub/?utm_source=stocktwits&utm_medium=social&utm_campaign=clym_hubpdf_nov26 Not investment advice.
0 replies